Credit Suisse, Cowen, Wells Fargo, Wedbush Securities assist with deal
By Devika Patel
Knoxville, Tenn., Nov. 4 – MyoKardia, Inc. said the underwriters for its initial public offering of stock opted to exercise the deal’s $8.16 million greenshoe in full, lifting total proceeds of the offering to $62.53 million on Tuesday. The deal was announced Sept. 28 and priced for $54.38 million with the greenshoe on Oct. 28.
The company sold 6,253,125 common shares at $10.00 apiece. Of the shares, 815,625 were part of the fully exercised greenshoe.
Credit Suisse Securities (USA) LLC and Cowen and Co. were the lead bookrunners and Wells Fargo Securities LLC was also a bookrunner.
Proceeds will be used for clinical development, preclinical, discovery and research programs, research and development activities, working capital and other general corporate purposes.
The South San Francisco, Calif., biopharmaceutical company seeks to treat serious and neglected rare cardiovascular diseases. The company intends to list its common stock on the Nasdaq stock exchange under the symbol “MYOK.”
| Issuer: | MyoKardia, Inc.
|
| Issue: | Common stock
|
| Amount: | $62,531,250, including $8,156,250 greenshoe of 815,625 shares
|
| Shares: | 6,253,125
|
| Price: | $10.00
|
| Warrants: | No
|
| Bookrunners: | Credit Suisse Securities (USA) LLC and Cowen and Co. (leads), Wells Fargo Securities LLC
|
| Co-manager: | Wedbush PacGrow
|
| Announcement date: | Sept. 28
|
| Pricing date: | Oct. 28
|
| Settlement date: | Nov. 3
|
| Stock symbol: | Nasdaq: MYOK
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
